After-surgery treatment study for stomach and colon cancer
Part of Cancer, Digestive system clinical trials.
This trial studies an additional (adjuvant) treatment after surgery for certain stage III stomach or colon cancers. It aims to lower the risk of the cancer coming back after a complete surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old and can participate as a man or woman
- You had stomach or colon cancer surgery with successful complete removal (R0 resection)
- Your cancer is stage III: stage III stomach cancer or stage III colon cancer (with lymph nodes involved and no distant spread)
- You are well enough overall (ECOG 0 to 2) and your major organs are working normally
- You have not had any cancer treatment before the surgery (no chemo, radiation, or targeted drugs)
- You cannot be pregnant or breastfeeding, and you must use effective birth control if you could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (lenvatinib, tislelizumab, and CapeOX chemotherapy) as the first treatment for advanced stomach or gastroesophageal junction cancer that is PD-L1 positive and has a low TMEscore. The goal is to see if this combination helps control the cancer better than standard treatments.
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
This Phase 1/2 trial tests a combination treatment for advanced or metastatic stomach and food-pipe (gastroesophageal junction) cancer: a chemotherapy regimen (CapeOX) plus the immunotherapy drug sintilimab and the targeted drug bevacizumab. It aims to see how well this combination controls the cancer and how safely it can be given.
This trial tests different adjuvant treatments for patients who had stomach or gastroesophageal junction cancer, received chemotherapy with immunotherapy before surgery, and had a complete response (no cancer left) in the surgical sample. It aims to find which treatment works best to prevent the cancer from coming back.
This trial tests a combination of radiation, chemotherapy (SOX), and two targeted drugs (apatinib and camrelizumab) before and after surgery for stomach or gastroesophageal junction cancer. It aims to see if this approach is safe and effective.
This trial tests a new combination of drugs (QL1706 plus chemotherapy SOX) given before and after surgery for stomach or gastroesophageal junction cancer. It aims to shrink the tumor before surgery and help prevent recurrence afterward.
Hear when a new Adjuvant Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.